GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytori Cell Research Institute Inc (TSE:3750) » Definitions » Cash Ratio

Cytori Cell Research Institute (TSE:3750) Cash Ratio : 0.32 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Cytori Cell Research Institute Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Cytori Cell Research Institute's Cash Ratio for the quarter that ended in Dec. 2023 was 0.32.

Cytori Cell Research Institute has a Cash Ratio of 0.32. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Cytori Cell Research Institute's Cash Ratio or its related term are showing as below:

TSE:3750' s Cash Ratio Range Over the Past 10 Years
Min: 0.22   Med: 0.98   Max: 54.17
Current: 0.32

During the past 13 years, Cytori Cell Research Institute's highest Cash Ratio was 54.17. The lowest was 0.22. And the median was 0.98.

TSE:3750's Cash Ratio is ranked worse than
86.5% of 1504 companies
in the Biotechnology industry
Industry Median: 2.94 vs TSE:3750: 0.32

Cytori Cell Research Institute Cash Ratio Historical Data

The historical data trend for Cytori Cell Research Institute's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytori Cell Research Institute Cash Ratio Chart

Cytori Cell Research Institute Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.73 1.23 1.46 0.86 0.96

Cytori Cell Research Institute Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 0.96 0.73 0.50 0.32

Competitive Comparison of Cytori Cell Research Institute's Cash Ratio

For the Biotechnology subindustry, Cytori Cell Research Institute's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytori Cell Research Institute's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytori Cell Research Institute's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Cytori Cell Research Institute's Cash Ratio falls into.



Cytori Cell Research Institute Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Cytori Cell Research Institute's Cash Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash Ratio (A: Mar. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1123.05/1173.624
=0.96

Cytori Cell Research Institute's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=715.804/2231.096
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cytori Cell Research Institute  (TSE:3750) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Cytori Cell Research Institute Cash Ratio Related Terms

Thank you for viewing the detailed overview of Cytori Cell Research Institute's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytori Cell Research Institute (TSE:3750) Business Description

Traded in Other Exchanges
N/A
Address
1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
Cytori Cell Research Institute Inc developing a new clinical approach to cell therapy to provide better medical care to patients by providing medical care that responds to unmet medical needs based on innovative regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.

Cytori Cell Research Institute (TSE:3750) Headlines

No Headlines